Joseph De Angelo

• 
  www.bioinstruments.org/2007.124.0.html?&tx_ttnews[point - [Cached Version]
  Published on: 1/1/2007    Last Visited: 7/28/2008  

  Joseph De Angelo, Chief Development Officer at Curacyte, said, "This study of hemoximer in patients receiving IL-2 is important because it may reduce a dose limiting side effect of IL-2 and enable patients to receive a higher number of scheduled IL-2 doses.

• 
  www.tvm-capital.com/pages/news/2005/cur1207.php - [Cached Version]
  Published on: 12/7/2005    Last Visited: 12/9/2007  

  Joseph De Angelo, Chief Development Officer at Curacyte, said, "In this trial, PHP will be administered before patients develop shock and require catecholamines.

• 
  www.tvm-capital.com/pages/news/2005/cur0914.php - [Cached Version]
  Published on: 9/14/2005    Last Visited: 12/9/2007  

  Joseph De Angelo, Chief Development Officer at Curacyte, said, "Clinical trials of PHP have been conducted in patients who are in shock and being treated with vasopressors.

• 
  Apex Bioscience, Inc - Corporate Profile - [Cached Version]
  Published on: 8/5/2001    Last Visited: 8/5/2001  

  Joseph DeAngelo , MS is the acting Chief Operating Officer and Chief Scientific Officer.He was instrumental in creating Apex Bioscience , Inc. in 1993.He served as Vice President of Research at Strohtech , Inc. from 1984–1993.Mr. DeAngelo is an acknowledged expert in the field of nitric oxide biology and has led the development of nitric oxide technology at the Company.Under his guidance , Apex has formed multiple license agreements and developed and/or acquired key proprietary rights.His responsibilities include development of the Company's clinical programs and third party sponsored research programs.He earned a B.S. in biology and an M.S. in industrial microbiology at the Massachusetts Institute of Technology.

• 
  Apex Bioscience, Inc - Press Release 7/6/99 - [Cached Version]
  Published on: 5/24/2001    Last Visited: 8/5/2001  

  Joseph De Angelo , Chief Scientific Officer of Apex commented : Failure of the cardiovascular system , or NO-induced shock , is an extremely serious condition resulting in death in approximately 50 percent of cases.The current standard of care , catecholamines , is inadequate to treat these patients and may exacerbate the situation.Our phase II data demonstrated that VTR-PHP had the expected hemodynamic activity of a NO-scavenger and reduced the need for vasopressors in shock patients.Based on these data , we were able to design a trial with an accurately targeted patient population and mechanism-of-action specific endpoints.We believe these design advantages will enable us to overcome the shortcomings of previous trials and demonstrate that VTR-PHP is effective in addressing this unmet clinical need..
  
  NO is an important mediator in a number of essential biological functions such as blood pressure regulation , neurotransmission and host defense.
  ...
  Joseph De Angelo( 919 ) 405-4002 or

• 
  ApoLife: Team - [Cached Version]
  Published on: 2/5/2008    Last Visited: 2/5/2008  

  Joseph De Angelo is Vice President of Research and Chief Scientific Officer for Apex Bioscience, Inc., the US subsidiary of Curacyte AG and a member of the Curacyte Vorstand.He was one of the founding scientists Apex Bioscience and is an expert in yeast biology.He has been active for over ten years in the field of nitric oxide biology and is a well-recognized expert in the field.He is an inventor of eleven issued patents.Under his direction at Apex, the lead product, PHP, a hemoglobin-based nitric oxide scavenger, has been developed from pre-phase 1 and has now entered phase 3 clinical trials.

• 
  ApoLife: Team - [Cached Version]
  Published on: 2/5/2008    Last Visited: 2/5/2008  

  Joseph DeAngelo, M.S., Board of Director

• 
  Biotech Press - The Latest Press Releases from... - [Cached Version]
  Published on: 7/1/2003    Last Visited: 4/8/2004  

  Joseph DeAngelo, Chief Development Officer of Curacyte AG, stated:

• 
  Curacyte - [Cached Version]
  Published on: 10/10/2003    Last Visited: 10/10/2003  

  Joseph De Angelo:Chief Development Officer
  
  Joseph De Angelo is Chief Development Officer for Curacyte and was one of the founders of Apex Bioscience, Inc. in 1993.His responsibilities include preclinical and clinical development and regulatory affairs on a global basis.He began work on hemoglobin in the early 1980s, initially developing systems for expressing recombinant hemoglobin in yeast while Vice President of Research for Strohtech, Inc.He has been active for over ten years in the field of nitric oxide biology and is an acknowledged expert in the field.He is an inventor of eleven issued patents.Under his direction the lead product, PHP, a hemoglobin-based nitric oxide scavenger, has been developed from pre-Phase I and has now entered Phase III clinical trials.Joe De Angelo received both undergraduate and graduate training at the Massachusetts Institute of Technology.He was granted a B.S. degree in biology in 1974 and an M.S. degree in microbiology in 1978.

• 
  Curacyte - [Cached Version]
  Published on: 1/29/2003    Last Visited: 1/29/2003  

  Joseph De Angelo:Chief Development Officer
  
  Joseph De Angelo is Chief Development Officer for Curacyte and was one of the founders of Apex Bioscience, Inc. in 1993.His responsibilities include preclinical and clinical development and regulatory affairs on a global basis.He began work on hemoglobin in the early 1980s, initially developing systems for expressing recombinant hemoglobin in yeast while Vice President of Research for Strohtech, Inc.He has been active for over ten years in the field of nitric oxide biology and is an acknowledged expert in the field.He is an inventor of eleven issued patents.Under his direction the lead product, PHP, a hemoglobin-based nitric oxide scavenger, has been developed from pre-Phase I and has now entered Phase III clinical trials.Joe De Angelo received both undergraduate and graduate training at the Massachusetts Institute of Technology.He was granted a B.S. degree in biology in 1974 and an M.S. degree in microbiology in 1978.

Page:  1 2